Article Text

Download PDFPDF
HER2-positive breast cancer metastatic to intracranial meningioma: a case report
  1. Mikkaela McCormack1,
  2. Cesar Salinas-La Rosa2,
  3. Michael Murphy3,
  4. Stephen B Fox1
  1. 1 Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
  2. 2 Department of Anatomical Pathology, St. Vincent's Hospital, Fitzroy, Victoria, Australia
  3. 3 Department of Neurosurgery, St. Vincent's Hospital, Fitzroy, Victoria, Australia
  1. Correspondence to Dr Mikkaela McCormack, Department of Pathology, Peter MacCallum Cancer Centre, St. Andrews Place East Melbourne, Victoria 3002, Australia; mikkaela{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The successful introduction of trastuzumab and other novel tyrosine kinase inhibitors (TKI) for treatment of HER2-positive breast carcinoma has resulted in lengthened survival for affected patients. In the context of this increased survival time, it has since emerged that patients who would otherwise have succumbed to the systemic progression of their disease have an increased propensity to develop metastases within the central nervous system (CNS) when compared with their HER2-negative counterparts.1 Recent literature shows that these metastatic deposits respond poorly to TKI therapy, most likely due to their inability to penetrate the blood brain barrier.2

We write to inform you of the first known reported case documenting a HER2-positive breast carcinoma metastasising to an intracranial meningioma, without evidence of additional CNS involvement. This report serves to highlight our increasing understanding of the pathogenesis of brain metastasis, and how this growing knowledge should …

View Full Text


  • Contributors MMcC: manuscript preparation, slide review, manuscript guarantor; SF: slide review, study design, manuscript review, manuscript guarantor; CS: original diagnosis, manuscript review; MM: clinical review.

  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.